LexDanaLexDanabeta
Inventor

Kari Alitalo

Inventor
Helsinki, FI

Overview

72→
Patents
1997–2019
Patent span
Human necessities
Primary field (CPC A)

Patents· 72 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes29%
C07KPeptides29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C12NMicroorganisms or enzymes6%
G01NInvestigating or analysing materials by determining their chemical or physical properties4%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
C07HSugars2%
C12YEnzymes1%
A61LMethods or apparatus for sterilising materials or objects in general1%
PatentTitleYear
10,400,035Methods of protecting a solid organ transplant tissue with angiopoietin-2 antibodies20199,896,499'Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis'20189,260,526'Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy'20169,073,997'Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis'20158,940,695'Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy'20158,852,936'Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery'20148,759,286'Pharmaceutical compositions comprising a VEGF-D polypeptide'20148,637,262'Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof'20148,461,109'Method of enhancing the acceptance and/or healing of a skin graft'20138,455,453'Use of VEGF-D gene to prevent restenosis'20138,444,957'Methods of screening for neoplastic disease states'20138,445,234'Methods of making VEGF-D polypeptides'20138,357,669'Method of treatment for lymphedema comprising administering a polynucleotide encoding VEGF-D'20138,282,931'Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof'20128,278,098'Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins'20128,227,410'Methods of stimulating wound healing by administration of vascular endothelial growth factor D (VEGF-D)'20128,029,984'Materials and methods for colorectal cancer screening, diagnosis and therapy'20118,025,886'Modified VEGF-A with improved angiogenic properties'20117,947,472'Expression vectors and cell lines expressing vascular endothelial growth factor D'20117,928,061'Methods of using VEGF-D polypeptides'20117,902,149'Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins'20117,871,798'Mammalian cells that express VEGF-D polypeptides'20117,855,178'Growth factor binding constructs materials and methods'20107,829,091'Therapy targeting FLT4 (VEGER-3) expressed in blood vessels'20107,829,536'Method of treating lymphedema comprising administering VEGF-D'20107,807,412'VEGF-C ΔR226ΔR227 mutants and uses thereof'20107,794,756'Methods of using antibodies to VEGF-C'20107,785,803'Antibody diagnostic kits and methods of use'20107,727,761'Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof'20107,709,270'Vascular endothelial growth factor C (VEGF-C) protein diagnostic'20107,662,932'Vascular endothelial growth factor D (VEGF-D) polypeptides and methods of use'20107,638,489'Modulation of angiogenesis by Bartonella henselae'20097,611,711'VEGFR-3 inhibitor materials and methods'20097,566,566'Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins'20097,476,654'Method for modulating, regulating and/or stabilizing angiogenesis'20097,423,125'Antibodies to VEGF-C'20087,422,741'VEGFR-3 fusion proteins'20087,420,042'Soluble neuropilin/growth factor receptor fusion proteins'20087,410,639'Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use'20087,408,040'Antibodies to PDGF-D'20087,341,996'Processed vascular endothelial growth factor-B polypeptides'20087,309,604'Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins'20077,148,037'Platelet-derived growth factor D, DNA coding therefor, and uses thereof'20067,125,714'Progenitor cell materials and methods'20067,122,654'Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use'20067,105,481'Method for stimulating connective tissue growth or wound healing'20067,034,105'FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy'20066,974,816'Combination for the treatment of endothelial damage'20056,965,010'Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins'20056,958,147'Use of VEGF-C to prevent restenosis'20056,824,777'Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy'20046,818,220'Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof'20046,793,918'In vivo stimulation of angiogenic activity'20046,764,820'Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)'20046,730,658'Stimulation of lymphatic growth with an FLT4 ligand'20046,706,687'Platelet-derived growth factor D'20046,689,580'Growth factor'20046,645,933'Receptor ligand VEGF-C'20036,515,105'Neuropilin/growth factor complexes and uses thereof'20036,403,088'Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)'20026,361,946'Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof'20026,331,301'Antibodies specific for vascular endothelial growth factor-B'20016,245,530'Receptor ligand'20016,235,713'Vascular endothelial growth factor-D (VEGF-D) polypeptides'20016,221,839'FIt4 ligand and methods of use'20016,130,071'Vascular endothelial growth factor C (VEGF-C) .DELTA.Cys.sub.156 protein and gene, and uses thereof'20005,955,291'Antibodies recognizing tie receptor tyrosine kinase and uses thereof'19995,928,939'Vascular endothelial growth factor-b and dna coding therefor'19995,877,020'Promoter for the receptor tyrosine kinase, Tie'19995,840,693'Vascular endothelial growth factor-B'19985,776,755'FLT4, a receptor tyrosine kinase'19985,607,918'Vascular endothelial growth factor-B and DNA coding therefor'1997

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1997–2009Patents assigned to LUDWIG INST CANCER RES (25)· patent assignee history
1997–2008Patents assigned to UNIV HELSINKI LICENSING (15)· patent assignee history
1997–2019Based in Helsinki, FI· patent location history
1998–2013Based in Espoo, FI· patent location history
2002–2011Patents assigned to LICENTIA LTD (12)· patent assignee history
2006–2009Based in University of Helsinki, FI· patent location history
2008–2011Patents assigned to VEGENICS LTD (15)· patent assignee history
2011–2018Patents assigned to VEGENICS PTY LTD (16)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
LUDWIG INST CANCER RES251997–2009
VEGENICS PTY LTD162011–2018
UNIV HELSINKI LICENSING151997–2008
VEGENICS LTD152008–2011
LICENTIA LTD122002–2011
Locations
LocationPatentsSpan
Helsinki, FI471997–2019
Espoo, FI231998–2013
University of Helsinki, FI22006–2009